PURPOSE: To evaluate the efficacy of interstitial radiosurgery (IRS) for pineal parenchymal tumors (PPTs). PATIENTS AND METHODS: 18 consecutively admitted patients (twelve male and six female, age range 6-68 years, median age 34 years) with PPTs (eight pineocytomas, ten malignant PPTs) were treated at the authors' institution with IRS using stereotactically guided iodine-125 seed implantation ((125)I-IRS) as either primary or salvage therapy. The cumulative tumor surface dose ranged from 40 to 64 Gy. Adjuvant radiotherapy of the whole brain or the craniospine was done in patients with grade III and grade IV PPT. The median follow-up period was 57.4 months (range 6-134 months). RESULTS: Overall actuarial 5- and 8-year survival rates after IRS were 100% and 86% for pineocytomas, and the overall actuarial 5-year survival rate was 78% for high-grade PPTs. Follow-up magnetic resonance imaging showed complete remission in 72% (13/18) and partial remission in 28% (5/18) of the cases. One patient developed an out-of-field relapse 4 years after partial remission of a pineocytoma, which had already been treated with IRS. There was no treatment-related mortality. Treatment-related morbidity occurred in two patients only. CONCLUSION: This study indicates that stereotactic (125)I-IRS for the management of PPTs is quite efficient and safe. Due to the low rate of side effects, IRS may develop into an attractive alternative to microsurgery in de novo diagnosed pineocytomas. In malignant PPTs, IRS may be routinely applied in a multimodality treatment schedule supplementary to conventional irradiation.
PURPOSE: To evaluate the efficacy of interstitial radiosurgery (IRS) for pineal parenchymal tumors (PPTs). PATIENTS AND METHODS: 18 consecutively admitted patients (twelve male and six female, age range 6-68 years, median age 34 years) with PPTs (eight pineocytomas, ten malignant PPTs) were treated at the authors' institution with IRS using stereotactically guided iodine-125 seed implantation ((125)I-IRS) as either primary or salvage therapy. The cumulative tumor surface dose ranged from 40 to 64 Gy. Adjuvant radiotherapy of the whole brain or the craniospine was done in patients with grade III and grade IV PPT. The median follow-up period was 57.4 months (range 6-134 months). RESULTS: Overall actuarial 5- and 8-year survival rates after IRS were 100% and 86% for pineocytomas, and the overall actuarial 5-year survival rate was 78% for high-grade PPTs. Follow-up magnetic resonance imaging showed complete remission in 72% (13/18) and partial remission in 28% (5/18) of the cases. One patient developed an out-of-field relapse 4 years after partial remission of a pineocytoma, which had already been treated with IRS. There was no treatment-related mortality. Treatment-related morbidity occurred in two patients only. CONCLUSION: This study indicates that stereotactic (125)I-IRS for the management of PPTs is quite efficient and safe. Due to the low rate of side effects, IRS may develop into an attractive alternative to microsurgery in de novo diagnosed pineocytomas. In malignant PPTs, IRS may be routinely applied in a multimodality treatment schedule supplementary to conventional irradiation.
Authors: V Sturm; O Pastyr; W Schlegel; H Scharfenberg; H J Zabel; G Netzeband; S Schabbert; W Berberich Journal: Acta Neurochir (Wien) Date: 1983 Impact factor: 2.216
Authors: Toshinori Hasegawa; Douglas Kondziolka; Constantinos G Hadjipanayis; John C Flickinger; L Dade Lunsford Journal: Neurosurgery Date: 2002-10 Impact factor: 4.654
Authors: R I Jakacki; P M Zeltzer; J M Boyett; A L Albright; J C Allen; J R Geyer; L B Rorke; P Stanley; K R Stevens; J Wisoff Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544
Authors: A Jouvet; M Fèvre-Montange; R Besançon; E Derrington; G Saint-Pierre; M F Belin; J Pialat; C Lapras Journal: Acta Neuropathol Date: 1994 Impact factor: 17.088
Authors: Johannes Lutterbach; François Fauchon; Steven E Schild; Susan M Chang; Axel Pagenstecher; Benedikt Volk; Christoph Ostertag; Felix Momm; Anne Jouvet Journal: Neurosurgery Date: 2002-07 Impact factor: 4.654
Authors: M J R Runge; M Maarouf; S Hunsche; M Kocher; M I Ruge; F El Majdoub; H Treuer; R-P Mueller; J Voges; V Sturm Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: Maximilian I Ruge; Martin Kocher; Mohammad Maarouf; Christina Hamisch; Harald Treuer; Jürgen Voges; Volker Sturm Journal: Strahlenther Onkol Date: 2010-12-22 Impact factor: 3.621
Authors: Julien Dinkel; Christian Thieke; Christian Plathow; Patrick Zamecnik; Hermann Prüm; Peter E Huber; Hans-Ulrich Kauczor; Heinz-Peter Schlemmer; Christian M Zechmann Journal: Strahlenther Onkol Date: 2011-06-27 Impact factor: 3.621
Authors: Tomasz Rutkowski; Andrzej Wygoda; Marcin Hutnik; Krzysztof Składowski; Jerzy Wydmański; Adam Maciejewski; Cezary Szymczyk; Janusz Wierzgoń; Andrzej Orlef; Bogusław Maciejewski Journal: Strahlenther Onkol Date: 2010-08-30 Impact factor: 3.621
Authors: Faycal El Majdoub; Clemens Neudorfer; Tobias Blau; Martin Hellmich; Christian Bührle; Martina Deckert; Volker Sturm; Mohammad Maarouf Journal: Strahlenther Onkol Date: 2015-08-26 Impact factor: 3.621
Authors: David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2016-06-09 Impact factor: 12.300